Bristol Myer’s Squibb (BMS) has announced a $2.3bn investment in a manufacturing campus in Houston, Texas. The cost of the investment is over twice what the company had previously estimated it would be in a government application earlier this year. “Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.” Houston attracts pharma investment with JETI schemeBMS competitor Eli Lilly has also recently invested in manufacturing space in the Generation Park Management District, spending $6.5bn on an active pharmaceutical ingredients plant, a plan which they unveiled in September last year. “Texas is America’s jobs engine, thanks to our welcoming business climate, robust infrastructure, and skilled and growing workforce,” he added.